Retatrutide in 2026: What the Phase 3 Results Mean—and Why You Should Not Buy ‘Research’ Retatrutide

By SmashMeals Editorial · Published 2026-10-01 · Updated 2026-10-01

Retatrutide is generating enormous attention because it targets three hormone receptors—GIP, GLP-1 and glucagon—and 2026 Phase 3 topline results reported substantial average weight loss in several trial populations. But there is one sentence that matters more than the headline numbers:

Retatrutide is still investigational as of October 1, 2026.

Eli Lilly states that retatrutide has not been approved by any regulatory agency and warns people not to take products claiming to be retatrutide outside a Lilly-sponsored clinical trial. Read Lilly's retatrutide safety statement.

What does the peer-reviewed Phase 3 evidence show?

On September 29, 2026, the New England Journal of Medicine published the Phase 3 TRIUMPH-1 results. In the randomized, double-blind trial, 2,339 adults with obesity without diabetes received once-weekly retatrutide at 4 mg, 9 mg or 12 mg, or placebo, for 80 weeks.

Mean body-weight change was −17.6% at 4 mg, −23.7% at 9 mg and −25.0% at 12 mg, versus −3.9% with placebo under the treatment-regimen estimand. Gastrointestinal events were the most common adverse events. The study also reported improvements in prespecified knee-osteoarthritis and obstructive-sleep-apnea groups.

Read the peer-reviewed TRIUMPH-1 paper in NEJM.

These are trial averages, not predictions for an individual. Retatrutide remains investigational, and regulatory review has not established an approved indication, label or retatrutide-specific nutrition protocol.

What the evidence answers—and what it does not

Why “research retatrutide” is a red flag

A medication's name on a label does not prove identity, purity, dose or sterility. Lilly specifically warns that illicit products may contain unknown ingredients, contaminants, too much or too little active ingredient, or the wrong ingredient.

Retatrutide has not completed the FDA approval process. Lilly says launch depends on completion of its trials and regulatory approval. Until then, a product advertised as “retatrutide” outside a legitimate clinical trial is not an FDA-approved retatrutide prescription.

For broader context, the FDA also warns that unapproved versions of GLP-1 drugs do not undergo FDA's premarket review for safety, effectiveness and quality. Read the FDA's GLP-1 warning.

The nutrition lesson is already relevant

Even though nobody should be self-prescribing investigational retatrutide, the trial results reinforce an issue clinicians already face with current obesity medications: large weight loss can happen while appetite and total food intake are dramatically reduced.

A 2025 joint advisory from major obesity, nutrition and lifestyle-medicine organizations emphasizes adequate protein, nutrient density, resistance exercise, micronutrient adequacy and management of gastrointestinal symptoms during GLP-1-based therapy. Read the advisory.

That framework is more useful than trying to invent a “retatrutide diet” before the drug is even approved.

If future obesity drugs suppress appetite more, food quality matters more—not less

Imagine two plates that both contain 350 calories. One is mostly refined snack food. The other contains lean protein, vegetables, a quality carbohydrate and enough flavor to make it enjoyable. When appetite is normal, there may be room later in the day to compensate for a nutritionally weak meal. When appetite is very small, there may not be.

That is why the practical hierarchy matters:

1. Protein first. Protect the part of the meal most directly connected to muscle maintenance.
2. Micronutrient-dense foods next. Vegetables, fruit, dairy or alternatives, beans and other whole foods as tolerated.
3. Enough energy to function. Chronic severe under-eating is not the same thing as successful obesity treatment.
4. Fluids throughout the day. Low appetite can unintentionally reduce drinking too.
5. Resistance exercise when medically appropriate. Weight loss and strength are not interchangeable outcomes.

Do not chase the biggest percentage on the internet

The “best” obesity medication is not automatically the one with the highest mean trial weight loss. Your health history, treatment indication, side effects, contraindications, access, cost, goals and response matter. Trial averages do not predict one person's exact outcome.

That same logic applies to food. There is no universal 1,200-calorie or 100-gram-protein plan that fits everybody taking an appetite-altering medication.

For current, approved therapies, SmashMeals has food-focused resources for semaglutide, tirzepatide and a 7-day GLP-1 meal plan.

A better question than “Where can I get retatrutide?”

Ask: What habits would I need if my appetite became much smaller?

That answer is useful now, regardless of which medication your clinician prescribes:

• know which foods reliably give you protein;
• keep portions small enough that food is not wasted;
• have easy, reheatable meals available;
• keep fluids accessible;
• keep strength training in the plan if cleared to do it;
• track symptoms serious enough to discuss with your clinician.

Prepared meals can remove one variable. You can see the meal, portion it, reheat it and stop when comfortably full. Explore GLP-1-friendly meals or protein-first meals for smaller appetites.

The SmashMeals perspective

Lew Kizer describes the company's standard as “same founder. Same recipes. Same standard.” The obesity-drug market changes quickly, but that standard is useful: do not let rapidly changing medication headlines turn food into a science experiment. Start with recognizable food, clear portions and a repeatable routine.

Bottom line

Retatrutide may become an important obesity medicine. Right now, it remains investigational. Follow the science, not gray-market hype. If and when it is approved, the most useful nutrition questions will still be about protein, hydration, nutrient adequacy, tolerance and preserving strength.

Sources

• New England Journal of Medicine — Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
• Eli Lilly — What to know about retatrutide
• Eli Lilly — TRIUMPH-2 and TRIUMPH-3 topline results, July 23, 2026
• American Diabetes Association — 2026 retatrutide Phase 3 summary
• ClinicalTrials.gov — TRIUMPH-3
• FDA — Concerns with unapproved GLP-1 drugs

Medical note: This article is educational. Do not obtain or use an investigational drug outside a lawful clinical trial. Medication decisions belong with a licensed prescriber.